Exchange & Returns Information
Review Details
(0)
| Generic For | FEMARA |
|---|---|
| Active Ingredient | LETROZOLE |
| Strength | 2.5MG |
| Manufacturer | JOHNLEE PHARMACEUTICALS |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 300 TABLETS | $ 0.19 | $ 56.90 |
$ 48.36
Apply ZARVY26 (-15%)
You save $ 8.54
|
||
| 2 BOXES - 600 TABLETS | $ 0.19 | $ 114.90 |
$ 97.67
Apply ZARVY26 (-15%)
You save $ 17.24
|
||
| ★ Best Value 3 BOXES - 900 TABLETS | $ 0.19 |
2% $ 170.70
$ 166.90
|
$ 141.87
Apply ZARVY26 (-15%)
You save $ 25.04
|
Reference information will be available soon.
Femaford 2.5 is an oral anticancer medication containing letrozole 2.5mg, a non-steroidal aromatase inhibitor (AI) that plays a critical role in the management of hormone receptor-positive (HR+) breast cancer in postmenopausal women. It functions by selectively inhibiting the aromatase enzyme, thereby blocking the peripheral conversion of androgens to estrogens, which are key drivers of tumor proliferation in HR+ cancers. Femaford 2.5 is widely prescribed across various stages of breast cancer treatment—including neoadjuvant, adjuvant, and metastatic settings—and is a mainstay in long-term maintenance therapy for recurrence prevention. Additionally, it serves a growing role in reproductive health as an ovulation inducer for anovulatory infertility, especially in women with PCOS.
AntiCancer Drugs > HR+ Breast Cancer in Postmenopausal Women
Letrozole is approved as first-line endocrine therapy in postmenopausal women with hormone-sensitive breast cancer. It is used as an adjuvant therapy after surgery, as a neoadjuvant therapy prior to surgery, and as monotherapy in cases of metastatic disease. Its ability to suppress estrogen production makes it a cornerstone in long-term disease control.
AntiCancer Drugs > Advanced or Metastatic Breast Cancer
In combination with targeted therapies such as fulvestrant or CDK4/6 inhibitors (e.g., palbociclib, ribociclib), letrozole improves progression-free survival in patients with advanced HR+/HER2- breast cancer. This dual regimen is now standard in first-line metastatic endocrine treatment.
FEMTECH > Ovulation Induction for Infertility
Letrozole is frequently used off-label in infertility management for women with anovulation, particularly those with polycystic ovarian syndrome (PCOS). It facilitates follicular maturation by lowering estrogen feedback on the hypothalamus, leading to increased endogenous FSH secretion and improved ovulatory response.
Letrozole’s pharmacological action centers on aromatase inhibition, preventing the peripheral conversion of androgens into estrogens. In postmenopausal women, where ovarian estrogen production ceases, this peripheral conversion becomes the dominant source of estrogen. By blocking it, letrozole effectively reduces estrogen-dependent tumor growth. The drug is selective, sparing adrenal and ovarian steroidogenesis, and is considered well tolerated even with long-term use. In fertility applications, its estrogen-lowering effect promotes a natural hormonal rebound that can induce ovulation without overstimulating the ovaries.
Standard Breast Cancer Dose:
→ Letrozole: 2.5 mg orally once daily
→ Administered continuously without breaks through the 28-day cycle
→ Treatment duration varies depending on clinical setting (usually 5–10 years)
→ Suitable for adjuvant, neoadjuvant, and metastatic therapy
Combination Therapy:
→ Ribociclib: 600 mg orally once daily for 21 days, followed by 7 days off
→ Letrozole: 2.5 mg taken daily without interruption during the same 28-day cycle
→ Recommended for both pre- and postmenopausal women (with ovarian suppression if needed)
Ovulation Induction (Off-label):
→ Usual regimen: 2.5–5 mg daily for 5 days, beginning on day 3 or 5 of the menstrual cycle
→ Monitoring with transvaginal ultrasound advised to track follicular response
→ Dosage and cycle duration may be modified based on ovulatory outcomes
Additional Notes:
→ Can be taken with or without food
→ Take at the same time each day for best effect
→ If a dose is missed, take as soon as possible unless it’s near the next dose. Do not double up
→ Regular monitoring for bone health and lipid levels recommended for long-term users
Store in a cool, dry place below 25°C
Avoid exposure to moisture and direct sunlight
Keep tablets in original packaging until ready to use
Store out of reach of children
Do not consume if packaging is damaged or the expiration date has passed
Common: hot flashes, fatigue, dizziness, musculoskeletal pain, nausea
Less common: increased cholesterol levels, sleep disturbances, hair thinning, constipation
Rare: osteoporosis, bone fractures, liver enzyme abnormalities, cardiovascular risk
Consult a healthcare provider immediately if you experience chest discomfort, shortness of breath, or persistent bone pain.
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
